Aptevo Therapeutics (APVO) Competitors

$0.80
0.00 (0.00%)
(As of 05/17/2024 ET)

APVO vs. ADTX, SXTC, CMRA, HSTO, BLPH, ATHX, AMPE, EVFM, OBSV, and SPRC

Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Aditxt (ADTX), China SXT Pharmaceuticals (SXTC), Comera Life Sciences (CMRA), Histogen (HSTO), Bellerophon Therapeutics (BLPH), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), Evofem Biosciences (EVFM), ObsEva (OBSV), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.

Aptevo Therapeutics vs.

Aptevo Therapeutics (NASDAQ:APVO) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.

In the previous week, Aptevo Therapeutics had 2 more articles in the media than Aditxt. MarketBeat recorded 5 mentions for Aptevo Therapeutics and 3 mentions for Aditxt. Aditxt's average media sentiment score of 0.33 beat Aptevo Therapeutics' score of -0.39 indicating that Aditxt is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aptevo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aditxt
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 1.2% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aptevo Therapeutics has higher revenue and earnings than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo Therapeutics$3.11M1.05-$17.41MN/AN/A
Aditxt$640K0.75-$32.38MN/AN/A

Aptevo Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -5,016.31%. Aptevo Therapeutics' return on equity of -221.61% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -221.61% -110.89%
Aditxt -5,016.31%-1,614.64%-191.28%

Aptevo Therapeutics has a beta of 5.13, meaning that its stock price is 413% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Aditxt has a consensus price target of $61.00, indicating a potential upside of 2,934.83%. Given Aditxt's higher probable upside, analysts plainly believe Aditxt is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aditxt
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aptevo Therapeutics received 194 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.

CompanyUnderperformOutperform
Aptevo TherapeuticsOutperform Votes
198
52.66%
Underperform Votes
178
47.34%
AditxtOutperform Votes
4
44.44%
Underperform Votes
5
55.56%

Summary

Aptevo Therapeutics beats Aditxt on 10 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APVO vs. The Competition

MetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.26M$6.80B$5.24B$7.99B
Dividend YieldN/A2.72%44.24%3.91%
P/E RatioN/A10.51103.2115.05
Price / Sales1.05289.142,370.1481.39
Price / CashN/A34.4236.7931.98
Price / Book0.535.795.494.64
Net Income-$17.41M$138.82M$105.95M$217.28M
7 Day Performance-10.11%1.45%1.42%2.90%
1 Month Performance9.98%4.81%4.96%6.66%
1 Year Performance-98.93%-3.83%7.84%9.89%

Aptevo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADTX
Aditxt
1.9669 of 5 stars
$2.04
-5.6%
$61.00
+2,890.2%
-91.0%$490,000.00$640,000.000.0061Upcoming Earnings
SXTC
China SXT Pharmaceuticals
0 of 5 stars
$1.16
+18.4%
N/A-79.6%$534,000.00$1.97M0.0078High Trading Volume
CMRA
Comera Life Sciences
0 of 5 stars
$0.03
+59.4%
N/A-95.4%$652,000.00$1.00M-0.0512Gap Up
HSTO
Histogen
0 of 5 stars
$0.16
+6.7%
N/A-74.8%$683,000.00$3.77M-0.067News Coverage
Gap Up
BLPH
Bellerophon Therapeutics
1.3024 of 5 stars
$0.06
flat
$2.00
+3,471.4%
-99.4%$685,000.00N/A-0.0718Analyst Forecast
News Coverage
Gap Up
ATHX
Athersys
0 of 5 stars
$0.00
flat
N/A-99.5%$284,000.00$146,000.000.0024Analyst Forecast
Gap Down
AMPE
Ampio Pharmaceuticals
0 of 5 stars
$0.23
flat
N/A-95.6%$256,000.00N/A-0.026Analyst Forecast
News Coverage
Gap Down
EVFM
Evofem Biosciences
0 of 5 stars
$0.01
flat
N/A-99.2%$827,000.00$18.22M0.0037Gap Up
OBSV
ObsEva
0 of 5 stars
$0.00
flat
N/AN/A$156,000.00$20.11M0.0048Analyst Forecast
Gap Down
SPRC
SciSparc
0 of 5 stars
$1.21
-2.4%
N/A-92.3%$855,000.00$2.88M0.003

Related Companies and Tools

This page (NASDAQ:APVO) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners